Search the Community
Showing results for tags 'interleukin 36'.
Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Exogenous replacement of IL-36 antagonists may be a novel promising therapeutic target for PsA patients. PubMed, Rheumatology (Oxford), 09/03/2019. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.